Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Brain Communications · 2024-10-30 · 6 (6)
DOI: 10.1093/braincomms/fcae396 ↗At a glance
Übersichtsarbeit in Brain Communications, published online on 2024-11-07. Written by Florine Leipp and 7 co-authors. Institution: Shimadzu France SAS France, Noisiel, France. Cited 93 times so far (Crossref); 157 references. The full text is freely available (open access, CC BY 4.0). Funded by: Shimadzu Corporation.
Topics: Demenz
Abstract (original language)
Astrocytes are fundamental in neural functioning and homeostasis in the central nervous system. These cells respond to injuries and pathological conditions through astrogliosis, a reactive process associated with neurodegenerative diseases such as Alzheimer’s disease. This process is thought to begin in the early stages of these conditions. Glial fibrillary acidic protein (GFAP), a type III intermediate filament protein predominantly expressed in astrocytes, has emerged as a key biomarker for monitoring this response. During astrogliosis, GFAP is released into biofluids, making it a candidate for non-invasive diagnosis and tracking of neurodegenerative diseases. Growing evidence positions GFAP as a biomarker for Alzheimer’s disease with specificity and disease-correlation characteristics comparable to established clinical markers, such as Aβ peptides and phosphorylated tau protein. To improve diagnostic accuracy, particularly in the presence of confounders and comorbidities, incorporating a panel of biomarkers may be advantageous. This review will explore the potential of GFAP within such a panel, examining its role in early diagnosis, disease progression monitoring and its integration into clinical practice for Alzheimer’s disease management.
Subjects
Author keywords
Authors and institutions
- Shimadzu France SAS France, Noisiel, France.
- IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier, France.
- Shimadzu Europa GmbH, Duisburg, Germany.
ORCID profiles: Florine Leipp, Sylvain Lehmann
Funding
- Shimadzu Corporation
Cite
APA
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A. C., Lehmann, S., & Hirtz, C. (2024). Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review. Brain Communications, 6(6). https://doi.org/10.1093/braincomms/fcae396
Vancouver
Leipp F, Vialaret J, Mohaupt P, Coppens S, Jaffuel A, Niehoff AC, et al. Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review. Brain Communications. 2024;6(6). doi:10.1093/braincomms/fcae396
BibTeX
@article{Leipp2024,
author = {Leipp, Florine and Vialaret, Jérôme and Mohaupt, Pablo and Coppens, Salomé and Jaffuel, Aurore and Niehoff, Ann-Christin and Lehmann, Sylvain and Hirtz, Christophe},
title = {Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review},
journal = {Brain Communications},
year = {2024},
volume = {6},
number = {6},
doi = {10.1093/braincomms/fcae396}
}
EUVIMED